Embracing industrial symbiosis goes beyond ethical responsibility; it’s a chance for companies to lower costs, reduce ...

Novo Nordisk's (NVO) contract Ypsomed to supply the company with injection pens designed to deliver its next-gen obesity ...

Novo Nordisk's early data on Amycretin positions it as a potentially strong competitor to other oral obesity drugs, such as Lilly's orforglipron and Structure's GSBR-1290 ... several significant ...

With the transactions stated above, Novo Nordisk A/S owns a total of 21,348,485 B shares of DKK 0.10, corresponding to 0.5% of the share capital, as treasury shares. The total number of A and B shares ...

The leading healthcare company specializing in diabetes care was honored with awards under the Inspirational Brand, Fast Enterprise, and Corporate Excellence categories. This remarkable feat not only ...

adding that the company is on track with answers to regulators’ questions on the deal. “I’m not worried about a plan B.” What Bloomberg Intelligence Says: Novo Nordisk’s 11% 3Q beat for obesity drug ...

LONDON, Nov 6 (Reuters) - Novo Nordisk's (NOVOb.CO), opens new tab ... obesity drug 3:10 PM UTC Argentina's state-run oil company YPF will seek $2 billion in financing in the second quarter ...

even their letter O sometimes comes slashed in half. But, Denmark is also home to what is suddenly Europe's largest company—Novo Nordisk…. a pharmaceutical firm with a market cap of a half ...

Novo Nordisk, after mulling the implications of ... whether ocedurenone showed potential in other therapeutic areas. The company had previously alluded to plans to launch phase 3 trials in ...

Novo Nordisk on Wednesday reported a third-quarter beat on sales of its blockbuster weight-loss drug Wegovy and narrowed its 2024 full-year growth guidance. Company shares jumped early on ...

Novo Nordisk’s third-quarter sales growth was slightly below our expectations, but we’re maintaining our DKK 600/$86 fair value estimates, as management’s narrowed full-year 2024 guidance ...